Solís-Sánchez KA, Miranda-Madrazo MR, Rendón-Macías ME, Villa-Bahena S, Ramírez-Silva H, Díaz-Caneja AR

Language: Spanish
References: 12
Page: 52-57
PDF size: 304.99 Kb.

ABSTRACT

Pulmonary hemorrhage (PH) in newborns is a serious complication that can cause death. Objective: to evaluate the impact of antihemorrhagic therapy—tranexamic acid (TA), eptacog alfa (EA), or aminocaproic acid (AA)—on newborns diagnosed with PH and treated in a Neonatal Intensive Care Unit. Material and methods: a retrospective cohort study was conducted involving 43 newborns diagnosed with PH between 2020 and 2024. All patients received one or more of the three antihemorrhagic agents, in addition to standard supportive care. Treatment outcomes were assessed based on survival, bleeding control, transfusion requirements, and recovery of hemoglobin and platelet levels. Results: of the 43 newborns included, 86% were preterm. A single antihemorrhagic agent was administered to 35 patients (TA: n = 8; EA: n = 19; AA: n = 8), while eight patients (18.6%) received a combination of two drugs. The overall survival rate was 79%, with nine deaths observed. Following initiation of antihemorrhagic therapy, transfusion requirements decreased across all cases. However, by the end of follow-up, eight patients (18.6%) remained anemic and five (11.6%) had thrombocytopenia. No differences in outcomes were observed among the three drugs used. Conclusion: antihemorrhagic therapy may offer clinical benefits in the management of PH in newborns. Nevertheless, further studies are needed to establish the efficacy and safety of these agents, particularly to clarify potential differences between EA, TA, and AA.

REFERENCES

1. Welde MA, Sanford CB, Mangum M, Paschal C, Jnah AJ. Pulmonary hemorrhage in the neonate. Neonatal Netw. 2021; 40(5): 295-304.

2. Escribá A, Gil R, Del Río R. Trastornos hemorrágicos en el recién nacido. An Pediatr. 2010; 8(2): 64-72.

3. Yen TA, Wang CC, Hsieh WS, Chou HC, Chen CY, Tsao PN. Short-term outcome of pulmonary hemorrhage in very-low-birth-weight preterm infants. Pediatr Neonatol. 2013; 54(5): 330-334.

4. Niles SD, Burkhart HM, Duffey DA, Buhrman K, Burzynski J, Holt DW. Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery. J Extra Corpor Technol. 2008; 40(4): 241-248.

5. Cosar H, Isik H, Cakir SC et al. Recombinant activated factor VIIa (rFVIIa) treatment in very-low-birth-weight (VLBW) premature infants with acute pulmonary hemorrhage: a single-center, retrospective study. Paediatr Drugs. 2017; 19(1): 53-58.

6. Can E, Hamilcikan S. Efficay of tranexamic acid in pulmonary hemorrhage in a asphyctic neonate. Iran J Ped Hematol Oncol. 2018; 8(2): 139-141.

7. Grizelj R, Vukovic J, Filipovic-Grcic B, Saric D, Luetic T. Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. Blood Coagul Fribilolysis. 2006; 17(5): 413-415. doi: 10.1097/01.mbc.000233373.71970.6f.

8. Rodríguez JD. Intervenciones farmacológicas para manejo del sangrado perioperatorio en niños. Rev Mex Anest. 2017; 41(1): 55-58.

9. Agarwal HS, Bennett JE, Churchwell KB et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007; 84(1): 161-168.

10. Siddiqui MA, Scott LJ. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs. 2005; 65(8): 1161-1177. doi: 10.2165/00003495-200565080-00008.

11. Lazner M, Cole J. Paediatric massive haemorrhage protocol. Brighton and Sussex NHS University Hospitals Trust; 2019. Available in: https://nationalbloodtransfusion.co.uk/sites/default/files/documents/2023-03/Paediatric%20Major%20Haemorrhage%20Protocol%20Brighton%20%26%20Sussex%20Hospital%202019.pdf

12. Raykateeraroj N, Kongsayreepong S, Duangpamorn N, Komoltri C, Subtaweesin T. Efficacy and safety of intraoperative intravenous tranexamic acid in neonates and infants weighing less than 5 kg undergoing congenital cardiac surgery: an exploratory retrospective cohort study. Thai J Anesthesiol. 2023; 49(1): 21-36.